Search for: "Ranbaxy Laboratories Limited "
Results 1 - 20
of 47
Sort by Relevance
|
Sort by Date
24 May 2021, 7:34 am
A federal judge has approved multiple classes in litigation accusing Indian generic drugmaker Ranbaxy Laboratories Ltd of delaying the launch of generic drugs by submitting false applications to U.S. regulators. [read post]
16 Apr 2018, 2:48 pm
Ranbaxy Laboratories Ltd., Ranbaxy soughtto limit a claim depicting a specific three-dimensionalorientation to a racemic mixture. 457 F.3d 1284, 1288–89(Fed. [read post]
2 Jul 2017, 12:52 am
However, where the specification sets out an explicit “promise”, utility will be measured against that promise: Consolboard; Pfizer v.Canada (Minister of Health), 2008 FCA 108, [2009] 1 F.C.R. 253 (Ranbaxy). [read post]
1 Jul 2017, 9:39 am
However, where the specification sets out an explicit “promise”, utility will be measured against that promise: Consolboard; Pfizer v.Canada (Minister of Health), 2008 FCA 108, [2009] 1 F.C.R. 253 (Ranbaxy). [read post]
6 Apr 2015, 7:51 am
The agreement is subject to customary regulatory review, Sun Pharmaceutical Industries said.Meanwhile, trading in shares of Ranbaxy Laboratories was suspended from today, 6 April 2015 as the swap ratio of Ranbaxy Laboratories and Sun Pharmaceutical Industries became effective after Sun Pharmaceutical Industries completed the merger of Ranbaxy Laboratories with itself.Sun Pharmaceutical Industries has set 7 April 2015 as the record date in order… [read post]
25 Oct 2014, 9:01 pm
Hill-Rom argued that adding this limitation overcame the obviousness rejection because this added limitation was not disclosed in the Ulrich reference[.] [read post]
18 Jul 2014, 11:55 am
This post is only from the Reed Smith (more properly, the non-Dechert) side of the blog.One hundred what, you say? [read post]
20 Feb 2014, 9:39 am
Ranbaxy Laboratories Ltd., 457 F.3d 1284 (Fed. [read post]
18 Feb 2014, 12:43 pm
Ranbaxy Laboratories Ltd., 457 F.3d 1284 (Fed. [read post]
10 Oct 2013, 8:42 am
Ranbaxy USA Inc. ($500 Million) Ranbaxy USA Inc., a subsidiary of Indian generic pharmaceutical manufacturer Ranbaxy Laboratories Limited, agreed to pay a total of $500 million to settle criminal and civil allegations filed against the company. [read post]
18 Sep 2013, 1:51 am
Nor is this overseas imposition of U.S. regulation on Non-U.S. companies limited just to companies in the financial sector. [read post]
30 Jun 2013, 1:12 pm
Interestingly, two of studies were conducted in a laboratory and the other did not measure half-life at all. [read post]
10 Jun 2013, 11:23 am
Kumar also disclosed to Thakur that the fabricated test results were not limited to the ARVs Ranbaxy had been producing; rather inventing false data and covering up original test data had been a common practice throughout the company for years. [read post]
3 Jun 2013, 8:38 am
Next up: another pharmaceutical company, Ranbaxy Laboratories, Ltd. [read post]
21 May 2013, 2:26 pm
Earlier this month, the Department of Justice announced a $500 million settlement it reached with Ranbaxy USA Inc., a subsidiary of the Indian generic pharmaceutical manufacturer Ranbaxy Laboratories Limited. [read post]
14 May 2013, 10:50 am
Ranbaxy USA Inc., the American subsidiary of Ranbaxy Laboratories Limited, an Indian generic pharmaceutical maker, has agreed to pay $500 million to settle fines related to claims that it made false statements to the FDA about its manufacturing practices abroad and sold substandard medications and pay penalties. [read post]
13 May 2013, 7:58 am
Ranbaxy Laboratories, Ltd., et al. , Case No. [read post]
3 Mar 2013, 12:06 pm
Patil 337/DELNP/2003 LANXESS DEUTSCHLAND GMBH Granted Dr.Rajesh Dixit 4069/DELNP/2006 RANBAXY LABORATORIES LIMITED Withdrawn Hardev Karar 106/DELNP/2008 ALFA WASSERMANN S. [read post]
18 Jan 2013, 2:06 pm
And if there’s another thing that’s not right, it’s imposing liability on a product manufacturer that didn’t make a cent (and probably was driven out of the market by) from the product that actually caused the injury in question.Nor is it very likely that this novel theory of “fraud/misrepresentation” liability can be limited to prescription drugs, whatever its intended scope. [read post]
29 Aug 2012, 10:09 pm
(“Merck”) (formerly Schering-Plough Corporation) restricted competition in violation of the Sherman Act by settling patent infringement lawsuits against potential generic K-DUR entrants, including Upsher-Smith Laboratories (“Upsher-Smith”). [read post]
